Views
1287 of 1287 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 NextCure, Inc.NXTC · | 3 assets: 2 Ph 1, 1 other | LNCB74Phase 1 · Non-Small Cell Lung Cancer | Dec 2026LNCB74 · Phase 1 |
 Nurix Therapeutics, Inc.NRIX · | 3 assets: 1 Ph 3, 1 Ph 1, 1 other | bexobrutidegPhase 3 · Relapsed/Refractory Chronic Lymphocytic Leukemia | Oct 2029bexobrutideg · Phase 3 |
 OCULAR THERAPEUTIX, INCOCUL · Nasdaq | 3 assets: 1 approved, 2 Ph 3 | OTX-TKIPhase 3 · Age-Related Macular Degeneration | 8 Jan 2027OTX-TKI · Phase 3 |
 OPKO HealthOPK · Nasdaq | 3 assets: 2 approved, 1 Ph 2 | OPK-88006Phase 1/2 · MASH / NASH | Oct 2027Extended-release calcifediol · Phase 2 |
 ORIC PharmaceuticalsORIC · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | ORIC-944Phase 3 · Prostate Cancer | Dec 2026ORIC-114 · Phase 1 |
 PTC TherapeuticsPTCT · Nasdaq | 3 assets: 2 approved, 1 Ph 3 | Vatiquinone (PTC743)Phase 3 · Friedreich Ataxia | 31 Dec 2027Vatiquinone (PTC743) · Phase 3 |
 Palatin TechnologiesPTN · NYSE | 3 assets: 1 Ph 3, 2 Ph 2 | PL9643Phase 3 · Dry Eye Disease | None on record |
 PegBioPrivate | 3 assets: 2 Ph 3, 1 Ph 2 | PB-119Phase 3 · Type 2 DiabetesReliable signal | None on record |
| 3 assets: 2 Ph 1, 1 other | UTAA09Phase 1 · Systemic Lupus ErythematosusWeak signal | 1 Apr 2027UTAA17 · Phase na | |
 Prothena Biosciences LimitedPRTA · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 other | PrasinezumabPhase 3 · Parkinson's Disease | 30 Jun 2029Prasinezumab · Phase 3 |
 Regend TherapeuticsPrivate | 3 assets: 1 Ph 3, 2 Ph 1 | REGEND001Phase 3 · Chronic Obstructive Pulmonary DiseasePartial signal | 15 Oct 2026REGEND007 · Phase 1 |
 Replimune, Inc.REPL · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | RP2Phase 2/3 · Solid Tumors | 31 Oct 2026RP2 · Phase 1 |
 Roivant Sciences Ltd.ROIV · Nasdaq | 3 assets: 1 approved, 2 Ph 3 | IMVT-1402Phase 3 · Myasthenia Gravis | Dec 2026Mosliciguat · Phase 2 |
 Rona TherapeuticsPrivate | 3 assets: 1 Ph 2, 2 Ph 1 | RN0361Phase 1/2 · Atherosclerotic Cardiovascular Disease | None on record |
 Samsung BioepisPrivate | 3 assets: 3 approved | Approved assets only | None on record |
 Sciwind BiosciencesPrivate | 3 assets: 2 Ph 3, 1 Ph 1 | ecnoglutidePhase 3 · ObesityReliable signal | 5 Jan 2027ecnoglutide · Phase 1/2 |
 SeagenPrivate | 3 assets: 1 approved, 1 Ph 3, 1 Ph 2 | Brentuximab VedotinPhase 3 · Non-Small Cell Lung CancerWeak signal | None on record |
| 3 assets: 2 Ph 3, 1 Ph 1 | PF-08046054Phase 3 · Non-Small Cell Lung Cancer | None on record | |
 Shanghai JMT-BioPrivate | 3 assets: 1 Ph 3, 2 Ph 2 | JMT101Phase 3 · Non-Small Cell Lung Cancer | 26 Mar 2027JMT101 · Phase 3 |
| 3 assets: 1 Ph 2, 2 Ph 1 | UX-DA003Phase 1/2 · Parkinson's Disease | Dec 2027UX-DA001 · Phase 1 | |
 Shenzhen TargetRxPrivate | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | TGRX-326Phase 3 · Non-Small Cell Lung Cancer | Feb 2027TGRX-1942 · Phase 1 |
 Sinocelltech Group Ltd.688520 · SSE | 3 assets: 3 Ph 3 | SCTB14Phase 3 · Non-Small Cell Lung Cancer | Apr 2027SCTC21C · Phase 1/2 |
 Stoke Therapeutics, Inc.STOK · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 other | ZorevunersenPhase 3 · Dravet Syndrome | Mar 2027Zorevunersen · Phase 3 |
 Sutro Biopharma, Inc.STRO · Nasdaq | 3 assets: 1 Ph 3, 2 Ph 1 | luveltamab tazevibulinPhase 2/3 · Ovarian Cancer | Dec 2027STRO-004 · Phase 1 |
 TG THERAPEUTICS, INC.TGTX · Nasdaq | 3 assets: 1 approved, 2 Ph 1 | Azercabtagene zapreleucelPhase 1 · Multiple Sclerosis | 31 Oct 2026Ublituximab · Phase 3 |
| 3 assets: 3 Ph 1 | BBO-10203Phase 1 · Non-Small Cell Lung Cancer | Aug 2027BBO-10203 · Phase 1 | |
 United TherapeuticsUTHR · Nasdaq | 3 assets: 2 approved, 1 Ph 3 | RalinepagPhase 3 · HypertensionReliable signal | Dec 2026Ralinepag · Phase 3 |
 Verastem, Inc.VSTM · Nasdaq | 3 assets: 2 approved, 1 Ph 2 | VS-7375Phase 2 · Non-Small Cell Lung Cancer | Jun 2027VS-7375 · Phase 2 |
 Viking TherapeuticsVKTX · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | VK2735Phase 3 · ObesityReliable signal | 1 Jul 2027VK2735 · Phase 3 |
 VistaGen TherapeuticsVTGN · Nasdaq | 3 assets: 2 Ph 3, 1 other | AV-101Phase 3 · Major Depressive DisorderPartial signal | None on record |
 Zydus LifesciencesZYDUSLIFE · NSE | 3 assets: 1 approved, 2 Ph 3 | DesidustatPhase 3 · Chronic Kidney DiseasePartial signal | 31 Dec 2026Saroglitazar · Phase 1 |
 ZymeworksZYME · Nasdaq | 3 assets: 2 approved, 1 Ph 3 | Ampreloxetine (TD-9855)Phase 3 · Neurogenic Orthostatic HypotensionPartial signal | 31 Dec 2026Zanidatamab · Phase 2 |
 uniQureQURE · Nasdaq | 3 assets: 1 approved, 2 Ph 2 | AMT-130Phase 1/2 · Huntington's Disease | 30 Nov 2026AMT-260 · Phase 1/2 |
 vTv TherapeuticsVTVT · Nasdaq | 3 assets: 1 Ph 3, 2 Ph 2 | cadisegliatinPhase 3 · Type 1 Diabetes | Apr 2027cadisegliatin · Phase 3 |
 1ST Biotherapeutics, Inc.Private | 2 assets: 2 Ph 1 | FB-101Phase 1 · Parkinson's DiseasePartial signal | Dec 2027FB-101 · Phase 1 |
 AB ScienceAB · Euronext Paris | 2 assets: 1 Ph 3, 1 Ph 2 | MasitinibPhase 3 · Alzheimer's DiseaseReliable signal | Dec 2027Masitinib · Phase 3 |
 ADARx PharmaceuticalsPrivate | 2 assets: 1 Ph 3, 1 Ph 1 | TelitaciceptPhase 3 · Systemic Lupus ErythematosusReliable signal | 31 Dec 2026Telitacicept · Phase 3 |
 AJU PharmPrivate | 2 assets: 2 Ph 3 | AJU-A51Phase 3 · Type 2 DiabetesPartial signal | None on record |
 ALX Oncology Inc.ALXO · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | EvorpaceptPhase 2/3 · Gastric Cancer | Jun 2027ALX2004 · Phase 1 |
| 2 assets: 2 approved | Approved assets only | None on record | |
| 2 assets: 2 other | Dihydroergotamine mesylate/Dipyrone/Caffeine (Cefaliv)Migraine | None on record | |
 Actinium PharmaceuticalsATNM · | 2 assets: 2 Ph 3 | Lintuzumab-Ac225Phase 3 · Acute Myeloid LeukemiaWeak signal | Feb 2029131I-apamistamab · Phase 2/3 |
 Adlai Nortye Biopharma Co., Ltd.ANL · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | BuparlisibPhase 3 · Head and Neck Squamous Cell Carcinoma | None on record |
 Agenus Inc.AGEN · | 2 assets: 2 Ph 3 | BalstilimabPhase 3 · Non-Small Cell Lung Cancer | Sep 2027Balstilimab · Phase 2 |
 Ahn-Gook Pharmaceutical001540 · KOSDAQ | 2 assets: 2 Ph 3 | AG2304RPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record |
 Akebia TherapeuticsAKBA · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | PraliciguatPhase 2 · Chronic Kidney Disease | Jun 2027Praliciguat · Phase 2 |
 Akros PharmaPrivate | 2 assets: 1 Ph 3, 1 Ph 2 | EnarodustatPhase 3 · Chronic Kidney DiseaseReliable signal | Jun 2027Enarodustat · Approved |
 Alentis Therapeutics AGPrivate | 2 assets: 2 Ph 2 | ALE.P02Phase 1/2 · Non-Small Cell Lung Cancer | 15 Feb 2028ALE.P02 · Phase 1/2 |
| 2 assets: 1 Ph 2, 1 Ph 1 | ALF201Phase 2 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record | |
 Allist Pharmaceuticals688578 · SSE STAR Market | 2 assets: 1 Ph 3, 1 Ph 1 | AlflutinibPhase 3 · Non-Small Cell Lung Cancer | Dec 2026AST2303 ABK3376 · Phase 1 |
 Allogene Therapeutics, Inc.ALLO · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | cemacabtagene ansegedleucelPhase 2 · Large B-Cell Lymphoma | Dec 2027cemacabtagene ansegedleucel · Phase 2 |
| 2 assets: 1 Ph 3, 1 Ph 2 | AZD3759Phase 2/3 · Non-Small Cell Lung CancerPartial signal | 23 Apr 2028Zorifertinib · Phase 1 | |
 AlphaTON Capital Corp.ATON · Nasdaq | 2 assets: 2 Ph 2 | TT-10Phase 1/2 · Non-Small Cell Lung Cancer | 1 Dec 2028TT-10 · Phase 1/2 |
 AlumisALMS · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | EnvudeucitinibPhase 3 · PsoriasisReliable signal | 1 Dec 2027Envudeucitinib · Phase 2 |
 AlvotechALVO · Nasdaq | 2 assets: 2 approved | Approved assets only | None on record |
 Anavex Life SciencesAVXL · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | BlarcamesinePhase 3 · Alzheimer's DiseaseReliable signal | None on record |
 Apollomics Inc.APLM · Nasdaq | 2 assets: 2 Ph 3 | UproleselanPhase 3 · Relapsed/Refractory Acute Myeloid Leukemia | None on record |
 Aptevo TherapeuticsAPVO · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | ALG.APV-527Phase 1/2 · Solid Tumors | Oct 2027APVO436 · Phase 1 |
 AronoraPrivate | 2 assets: 2 Ph 2 | AB002Phase 2 · Chronic Kidney DiseasePartial signal | None on record |
 Asahi Kasei Corporation3407 · TSE | 2 assets: 1 approved, 1 Ph 2 | GKT137831Phase 2 · Primary Biliary Cholangitis | Mar 2027Budesonide (targeted-release) · Approved |
 Ascendis Pharma Oncology Division A/SASND · Nasdaq | 2 assets: 2 approved | Approved assets only | None on record |
 Atom TherapeuticsPrivate | 2 assets: 1 Ph 3, 1 Ph 2 | ABP-671Phase 2/3 · Chronic Kidney Disease | 31 Oct 2027ABP-671 · Phase 2 |
 Attovia TherapeuticsPrivate | 2 assets: 2 Ph 1 | ATTO-1310Phase 1 · Atopic Dermatitis | None on record |
 Aurinia PharmaceuticalsAUPH · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | aritinerceptPhase 1/2 · Systemic Lupus Erythematosus | 2 Mar 2029Voclosporin · Approved |
 Avalo Therapeutics, Inc.AVTX · Nasdaq | 2 assets: 2 Ph 2 | AVTX-002Phase 2 · AsthmaPartial signal | None on record |
 Avistone BiotechnologyPrivate | 2 assets: 1 Ph 3, 1 Ph 2 | PLB1004Phase 3 · Non-Small Cell Lung Cancer | 31 Oct 2026PLB1004 · Phase 2 |
 BIAL - PortelaPrivate | 2 assets: 1 approved, 1 Ph 2 | ZamicastatPhase 2 · HypertensionPartial signal | None on record |
 Bambusa TherapeuticsPrivate | 2 assets: 2 Ph 2 | BBT001Phase 1/2 · Atopic Dermatitis | 31 Dec 2026BBT002 · Phase 1 |
| 2 assets: 2 Ph 1 | NK520Phase 1 · Acute Myeloid LeukemiaWeak signal | Jun 2027NK510 · Phase 1 | |
| 2 assets: 1 Ph 3, 1 Ph 2 | MIL62Phase 3 · Systemic Lupus Erythematosus | Dec 2028MIL62 · Phase 3 | |
 Beta Pharma, Inc.Private | 2 assets: 1 Ph 3, 1 Ph 2 | BPI-7711Phase 3 · Non-Small Cell Lung CancerWeak signal | None on record |
 BicycleTx LimitedBCYC · Nasdaq | 2 assets: 2 Ph 2 | Zelenectide pevedotinPhase 2 · Non-Small Cell Lung Cancer | Mar 2028Zelenectide pevedotin · Phase 2 |
| 2 assets: 1 Ph 2, 1 other | BCMA-CART (Bioray Laboratories)Phase 1/2 · Multiple Myeloma | 15 Mar 2027BRL-305 · | |
 BioXcel Therapeutics, Inc.BTAI · OTC | 2 assets: 2 approved | Approved assets only | 31 Jul 2027Dexmedetomidine (Igalmi) · Phase 1 |
 Biocon BiologicsPrivate | 2 assets: 1 approved, 1 Ph 1 | Bmab1700Phase 1 | 16 Aug 2027Bmab1700 · Phase 1 |
 Biotest AGPrivate | 2 assets: 1 Ph 3, 1 other | Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)Phase 3 · Chronic Hepatitis B | None on record |
 BlossomHill TherapeuticsBLSM · | 2 assets: 1 Ph 2, 1 Ph 1 | BH-30643Phase 1/2 · Non-Small Cell Lung Cancer | 31 Jan 2029BH-30643 · Phase 1/2 |
 BlueSphere BioPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | BSB-1001Phase 1/2 · Acute Myeloid Leukemia | None on record |
 BrightGene Bio-Medical Technology688166 · SSE | 2 assets: 1 Ph 3, 1 Ph 1 | BGM0504Phase 3 · ObesityPartial signal | 28 Feb 2027BGM0504 · Phase 2 |
 CARsgen Therapeutics Holdings Limited2171 · HKEX | 2 assets: 2 Ph 2 | Zevorcabtagene autoleucelPhase 1/2 · Multiple MyelomaWeak signal | 15 Jun 2027CT071 · Phase 1/2 |
 CASI Pharmaceuticals, Inc.CASIF · OTC | 2 assets: 1 approved, 1 Ph 2 | CID-103Phase 1/2 · Immune ThrombocytopeniaWeak signal | May 2030CID-103 · Phase 1/2 |
 COMPUGEN LTDCGEN · Nasdaq | 2 assets: 2 Ph 1 | COM902Phase 1 · Multiple MyelomaWeak signal | None on record |
 Calliditas TherapeuticsPrivate | 2 assets: 1 approved, 1 Ph 2 | GKT137831Phase 2 · Primary Biliary Cholangitis | Mar 2027Budesonide (targeted-release) · Approved |
 Can-Fite BioPharmaCANF · Nasdaq | 2 assets: 2 Ph 3 | NamodenosonPhase 3 · Hepatocellular CarcinomaPartial signal | 31 Aug 2027Piclidenoson · Phase 2 |
 Celldex TherapeuticsCLDX · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | barzolvolimabPhase 3 · Chronic Spontaneous Urticaria | Mar 2027CDX-622 · Phase 1 |
 Celon PharmaCLN · GPW | 2 assets: 2 Ph 2 | CPL500036Phase 2 · Parkinson's DiseaseReliable signal | None on record |
 Chengdu Kanghong Pharmaceutical002773 · SZSE | 2 assets: 2 Ph 3 | KH607Phase 3 · Major Depressive DisorderPartial signal | Dec 2027KH607 · Phase 3 |
| 2 assets: 1 Ph 3, 1 Ph 2 | Purinostat MesylatePhase 3 · Multiple Myeloma | 30 Dec 2026Purinostat Mesylate · Phase 2 | |
 Chugai Pharma4519 · TSE | 2 assets: 1 approved, 1 Ph 1 | AQUA07Phase 1 · Non-Small Cell Lung Cancer | 31 Aug 2030AQUA07 · Phase 1 |
 Compass TherapeuticsCMPX · Nasdaq | 2 assets: 1 Ph 1, 1 other | CTX-8371Phase 1 · Non-Small Cell Lung Cancer | Dec 2026CTX-8371 · Phase 1 |
 Corbus PharmaceuticalsCRBP · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | CRB-701Phase 3 · Cervical Cancer | 16 Jan 2027CRB-701 · Phase 1/2 |
 Covis PharmaPrivate | 2 assets: 2 approved | Approved assets only | None on record |
 Cumberland Pharmaceuticals Inc.CPIX · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | IfetrobanPhase 2 · Systemic Sclerosis | Jan 2028Ifetroban · Phase 2 |
 Curacle365270 · KOSDAQ | 2 assets: 2 Ph 2 | CU104Phase 2 · Ulcerative ColitisPartial signal | None on record |
 Currax PharmaceuticalsPrivate | 2 assets: 2 approved | Approved assets only | Jan 2029naltrexone/bupropion · Approved |
 Cycle Pharmaceuticals Ltd.Private | 2 assets: 2 approved | Approved assets only | None on record |
 Dizal Pharmaceuticals688192 · SSE STAR Market | 2 assets: 1 approved, 1 Ph 2 | DZD6008Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2026Sunvozertinib · Phase 2 |
 EMD SeronoPrivate | 2 assets: 2 approved | Approved assets only | None on record |
 Enanta Pharmaceuticals, Inc.ENTA · Nasdaq | 2 assets: 2 Ph 2 | EDP-323Phase 2 · Respiratory Syncytial Virus InfectionPartial signal | Dec 2026zelicapavir · Phase 2 |
 ErascaERAS · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | NaporafenibPhase 3 · MelanomaWeak signal | 5 Oct 2026Naporafenib · Phase 1 |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).